PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Prism Ideas CEO Acknowledged Among the Top 100 Most Inspiring People in the Pharmaceutical Industry - Prism Ideas CEO Acknowledged Among the Top 100 Most Inspiring People in the Pharmaceutical Industry - PrismIdeas.com
Prism Ideas CEO Acknowledged Among the Top 100 Most Inspiring People in the Pharmaceutical Industry

 

NewswireToday - /newswire/ - Holmes Chapel, Cheshire, United Kingdom, 2011/08/03 - Prism Ideas CEO Acknowledged Among the Top 100 Most Inspiring People in the Pharmaceutical Industry - PrismIdeas.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Prism Ideas, an independent global provider of medical communications and drug development consultancy services, today announced that Dr. James Sawyer, CEO, has been selected by PharmaVOICE magazine as one of the 100 most inspirational and influential people in the pharmaceutical industry. James has been recognised for his role in founding Prism Ideas and his sustained contribution to the advancement of pharmaceutical research, which has greatly enhanced the management and treatment options for debilitating illnesses. The PharmaVOICE 100 winners are nominated by the magazine’s readers based on the individual’s ability to inspire and positively impact on corporate leadership, research and development in the pharmaceutical industry.

“I am surprised and delighted to have been nominated to receive this prestigious award and to be listed alongside the other recipients,” James said,“At Prism Ideas we believe in putting patients and people first. The recognition represented by this award would not have been possible had I not been able to work with such innovative and pioneering individuals who share my vision of developing new strategies that advance processes within the industry to improve healthcare delivery.”

For almost 20 years, James has dedicated his efforts to the clinical application of pharmaceutical industry research. During his career, James has served the life sciences through a number of different roles, including clinical positions in general medicine and anaesthetics as well as in pharmaceutical clinical research. His experience as a specialist pharmaceutical physician spans all phases of clinical research and has resulted in more than 50 publications across a variety of therapeutic areas including migraine, bone metabolism, asthma and HIV.

As a leader in his field, James truly has a global vision that underpins the success he has driven in his early career and since forming Prism Ideas. The company provides its clients with a broad range of services from clinical program consultancy and clinical trial support to medical communications. Its team is committed to developing a unique range of services that deliver real improvements to how pharmaceutical companies manage their drug development processes and the commercialisation of new therapies. Over the past 10 years, James has led Prism Ideas through an exceptional growth period, which has seen it expand into overseas markets including Switzerland and the U.S.

Nigel Brooksby, non-executive chairman, Prism Ideas, comments: “Throughout his career, James has demonstrated an ability to apply exceptional talent in pharmaceutical medicine across diverse subjects and therapy areas. Always at the forefront of innovation, he has led Prism Ideas to become a pharmaceutical medicine consultancy operating at a global level.” Nigel continues,“James possesses a rare combination of exceptional business acumen and whole-hearted devotion to medical science. I have worked with many physicians and have found his entrepreneurial skills and thorough understanding of the medical profession to be unique.”

For further information about Prism Ideas, please call +44 (0) 1270 621 724 or visit prismideas.com/.

About Prism Ideas

Prism Ideas (prismideas.com) is an independent company providing drug development consultancy and expert medical affairs support to the pharmaceutical industry. The company offers a full range of medical communications services including congress materials, journal articles, publication plans, advisory boards and advocacy development; drug development consultancy and expert medical support throughout the clinical evaluation drugs from medical monitoring of early stage clinical studies through to post-marketing activities.

Prism’s knowledge of industry, together with a thorough understanding of the science, ensures that clinical trials and medical communications maintain the highest scientific quality whilst meeting the needs of the pharmaceutical industry.

Prism currently has offices in the UK, Switzerland and the U.S.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Prism Ideas CEO Acknowledged Among the Top 100 Most Inspiring People in the Pharmaceutical Industry

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: ScottPR.com 
+44 1477 539539 prism[.]scottpr.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)